Effects of Oral Melatonin Supplementation on Inflammatory and Oxidative Stress Markers, Metabolic Parameters, Blood Pressure, and Sleep Quality in Patients With Stage 3 - 4 Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Jundishapur Journal of Natural Pharmaceutical Products · 03.05.2026 · 21 (1)
DOI: 10.5812/jjnpp-170199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jundishapur Journal of Natural Pharmaceutical Products, online erschienen am 03.05.2026. Verfasst von Shadi Ziaie und 5 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is a growing global health burden characterized by progressive renal decline, chronic inflammation, oxidative stress, and frequent sleep disturbances. Melatonin, an endogenous regulator of circadian rhythm with antioxidant and anti-inflammatory properties, has been proposed as a potential adjunctive therapy in CKD.
Objectives
To evaluate the effects of oral melatonin supplementation on inflammatory markers, oxidative stress, metabolic parameters, blood pressure, and sleep quality in non-dialysis patients with CKD stages 3 - 4.
Methods
In this randomized, double-blind, placebo-controlled clinical trial enrolled 73 non-dialysis patients with CKD stages 3 - 4 (glomerular filtration rate < 60 mL/min/1.73 m²). Participants were randomly assigned to receive either oral melatonin (3 mg/day) or matching placebo for 12 weeks. Serum levels of interleukin-1β (IL-1β), malondialdehyde (MDA), blood pressure, sleep quality, and routine biochemical parameters were measured at baseline and post-intervention.
Results
After 12 weeks, no significant changes were observed in IL-1β or MDA levels in either group (P > 0.05). The MDA decreased in the melatonin group (-0.39 ± 9.36) and slightly increased in the placebo group (0.69 ± 4.93; between-group P = 0.313). Melatonin supplementation yielded a significant reduction in total cholesterol compared with placebo. Regarding sleep quality, both groups showed slight numerical changes, but the melatonin group exhibited a relatively more favorable trajectory, a smaller mean decline in PSQI score (-0.18 ± 0.84) compared with placebo (-0.69 ± 1.06; P = 0.047).
Conclusions
Twelve-week melatonin supplementation did not significantly alter inflammatory or oxidative stress markers in stage 3 - 4 CKD but was well tolerated and demonstrated modest metabolic and sleep-related benefits. Larger and longer studies are warranted to clarify its clinical relevance and mechanistic pathways in this population.
Zitieren
APA
Ziaie, S., Pourrezagholie, F., Niri, A. N., Mahdavi, B., Abbasinazari, M., & Asadpour, R. (2026). Effects of Oral Melatonin Supplementation on Inflammatory and Oxidative Stress Markers, Metabolic Parameters, Blood Pressure, and Sleep Quality in Patients With Stage 3 - 4 Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Jundishapur Journal of Natural Pharmaceutical Products, 21(1). https://doi.org/10.5812/jjnpp-170199
Vancouver
Ziaie S, Pourrezagholie F, Niri AN, Mahdavi B, Abbasinazari M, Asadpour R. Effects of Oral Melatonin Supplementation on Inflammatory and Oxidative Stress Markers, Metabolic Parameters, Blood Pressure, and Sleep Quality in Patients With Stage 3 - 4 Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Jundishapur Journal of Natural Pharmaceutical Products. 2026;21(1). doi:10.5812/jjnpp-170199
BibTeX
@article{Ziaie2026,
author = {Ziaie, Shadi and Pourrezagholie, Fatemeh and Niri, Aylar Nadiri and Mahdavi, Behnam and Abbasinazari, Mohammad and Asadpour, Roja},
title = {Effects of Oral Melatonin Supplementation on Inflammatory and Oxidative Stress Markers, Metabolic Parameters, Blood Pressure, and Sleep Quality in Patients With Stage 3 - 4 Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial},
journal = {Jundishapur Journal of Natural Pharmaceutical Products},
year = {2026},
volume = {21},
number = {1},
doi = {10.5812/jjnpp-170199}
}
EUVIMED